Saniona AB (publ) (SANION.ST)
SEK 8.05
(3.34%)
SEK 8.05
(3.34%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 86.08 Million SEK | -14.76% |
| 2022 | 100.98 Million SEK | -36.18% |
| 2021 | 158.24 Million SEK | 78.36% |
| 2020 | 88.72 Million SEK | 136.2% |
| 2019 | 37.56 Million SEK | -13.88% |
| 2018 | 43.61 Million SEK | 305.86% |
| 2017 | 10.74 Million SEK | -34.93% |
| 2016 | 16.51 Million SEK | 249.2% |
| 2015 | 4.73 Million SEK | -29.19% |
| 2014 | 6.68 Million SEK | -53.92% |
| 2013 | 14.49 Million SEK | 51.63% |
| 2012 | 9.56 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 80.43 Million SEK | -6.56% |
| 2024 Q2 | 85.52 Million SEK | 6.33% |
| 2023 Q3 | 87.73 Million SEK | -11.64% |
| 2023 FY | 86.08 Million SEK | -14.76% |
| 2023 Q1 | 99.21 Million SEK | -1.76% |
| 2023 Q4 | 86.08 Million SEK | -1.88% |
| 2023 Q2 | 99.28 Million SEK | 0.08% |
| 2022 Q1 | 182.33 Million SEK | 15.22% |
| 2022 Q3 | 101.29 Million SEK | -31.42% |
| 2022 Q4 | 100.98 Million SEK | -0.3% |
| 2022 FY | 100.98 Million SEK | -36.18% |
| 2022 Q2 | 147.7 Million SEK | -18.99% |
| 2021 Q4 | 158.24 Million SEK | 10.18% |
| 2021 FY | 158.24 Million SEK | 78.36% |
| 2021 Q3 | 143.62 Million SEK | 111.96% |
| 2021 Q2 | 67.76 Million SEK | 6.98% |
| 2021 Q1 | 63.34 Million SEK | -28.61% |
| 2020 Q4 | 88.72 Million SEK | -7.79% |
| 2020 Q1 | 48.65 Million SEK | 29.53% |
| 2020 FY | 88.72 Million SEK | 136.2% |
| 2020 Q2 | 73.01 Million SEK | 50.06% |
| 2020 Q3 | 96.21 Million SEK | 31.78% |
| 2019 Q4 | 37.56 Million SEK | -3.2% |
| 2019 FY | 37.56 Million SEK | -13.88% |
| 2019 Q1 | 50.82 Million SEK | 16.52% |
| 2019 Q2 | 62.37 Million SEK | 22.72% |
| 2019 Q3 | 38.8 Million SEK | -37.79% |
| 2018 Q3 | 11.52 Million SEK | -56.8% |
| 2018 FY | 43.61 Million SEK | 305.86% |
| 2018 Q4 | 43.61 Million SEK | 278.4% |
| 2018 Q1 | 19.34 Million SEK | 79.98% |
| 2018 Q2 | 26.68 Million SEK | 37.94% |
| 2017 Q1 | 10.9 Million SEK | -34.01% |
| 2017 FY | 10.74 Million SEK | -34.93% |
| 2017 Q3 | 12.2 Million SEK | 0.59% |
| 2017 Q4 | 10.74 Million SEK | -11.96% |
| 2017 Q2 | 12.13 Million SEK | 11.33% |
| 2016 Q2 | 8.18 Million SEK | -13.24% |
| 2016 Q1 | 9.43 Million SEK | 99.41% |
| 2016 FY | 16.51 Million SEK | 249.2% |
| 2016 Q4 | 16.51 Million SEK | 3.15% |
| 2016 Q3 | 16.01 Million SEK | 95.69% |
| 2015 Q4 | 4.73 Million SEK | -64.27% |
| 2015 FY | 4.73 Million SEK | -29.19% |
| 2015 Q1 | 9.5 Million SEK | 42.31% |
| 2015 Q2 | 12.66 Million SEK | 33.23% |
| 2015 Q3 | 13.24 Million SEK | 4.54% |
| 2014 FY | 6.68 Million SEK | -53.92% |
| 2014 Q2 | 10.22 Million SEK | 0.0% |
| 2014 Q3 | 7.4 Million SEK | -27.59% |
| 2014 Q4 | 6.68 Million SEK | -9.8% |
| 2013 FY | 14.49 Million SEK | 51.63% |
| 2012 FY | 9.56 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 19.243% |
| Ziccum AB (publ) | 6.38 Million SEK | -1247.574% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -3549.131% |
| BioArctic AB (publ) | 139.5 Million SEK | 38.293% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -148.773% |
| Mendus AB (publ) | 51.22 Million SEK | -68.049% |
| Genovis AB (publ.) | 98.04 Million SEK | 12.202% |
| Intervacc AB (publ) | 21.68 Million SEK | -297.062% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -222.312% |
| Active Biotech AB (publ) | 13.4 Million SEK | -542.41% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 30.566% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -434.113% |
| Aptahem AB (publ) | 8.99 Million SEK | -856.709% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -110.683% |
| Kancera AB (publ) | 17.97 Million SEK | -378.824% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -86.408% |
| Fluicell AB (publ) | 8.91 Million SEK | -865.597% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -1568.922% |
| Biovica International AB (publ) | 34.76 Million SEK | -147.6% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -637.77% |
| AcouSort AB (publ) | 10.37 Million SEK | -729.476% |
| Xintela AB (publ) | 14.01 Million SEK | -514.22% |
| Abliva AB (publ) | 16.78 Million SEK | -412.979% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 59.887% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -644.083% |
| OncoZenge AB (publ) | 1.69 Million SEK | -4966.686% |
| Amniotics AB (publ) | 10.54 Million SEK | -716.185% |
| 2cureX AB (publ) | 2.93 Million SEK | -2832.981% |
| CombiGene AB (publ) | 4.15 Million SEK | -1971.295% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -1844.939% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 94.502% |
| Camurus AB (publ) | 414.81 Million SEK | 79.248% |
| Corline Biomedical AB | 6.78 Million SEK | -1167.978% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -40.299% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -349.191% |
| I-Tech AB | 16.2 Million SEK | -431.213% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 92.741% |
| Cyxone AB (publ) | 4.69 Million SEK | -1733.894% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -545.881% |
| Biosergen AB | 5.08 Million SEK | -1592.881% |
| Cantargia AB (publ) | 54.97 Million SEK | -56.6% |
| NextCell Pharma AB | 13.68 Million SEK | -528.845% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -19.809% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -525.077% |
| Nanologica AB (publ) | 79.32 Million SEK | -8.517% |
| SynAct Pharma AB | 51.83 Million SEK | -66.074% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -982.941% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -1557.054% |
| LIDDS AB (publ) | 3.75 Million SEK | -2191.88% |
| Lipum AB (publ) | 7.53 Million SEK | -1041.987% |
| BioInvent International AB (publ) | 90.45 Million SEK | 4.831% |
| Alzinova AB (publ) | 9.33 Million SEK | -822.548% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 52.597% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -4698.384% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -365.464% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -2142.913% |
| Simris Alg AB (publ) | 148.93 Million SEK | 42.202% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -21.042% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 82.147% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -575.479% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -1085.716% |